🍎 🍕 Less apples, more pizza 🤔 Have you seen Buffett’s portfolio recently?Explore for Free

Truist raises Viking Therapeutics stock target to $120 on GLP1 profile

EditorNatashya Angelica
Published 02/29/2024, 10:27 AM
© Reuters.
VKTX
-

On Thursday, Truist Securities adjusted its outlook on Viking Therapeutics (NASDAQ:VKTX), significantly increasing the stock price target for the biopharmaceutical company's shares to $120 from the previous target of $38. The firm maintained its Buy rating on the stock.

The price target revision follows the analysis of new data regarding Viking Therapeutics' product VK2735, which is being developed for obesity and diabetes management. The drug has shown promising results, with evidence pointing to a best-in-class GLP1 (glucagon-like peptide-1) profile.

According to the analyst, VK2735 is approximately twice as effective in promoting weight loss when compared to tirzepatide, and it also exhibits numerical superiority over retatrutide, a triple agonist. This is coupled with a superior tolerability profile.

The firm's confidence in VK2735 is further bolstered by the introduction of a diabetes market model, which expands the drug's total addressable market (TAM). Truist Securities projects non-risk adjusted peak sales for VK2735 in the United States to reach $35 billion by the year 2043, covering both obesity and diabetes indications.

The potential for Viking Therapeutics' stock is further underscored by the anticipation of phase 1 data for an oral version of VK2735, which is expected in the upcoming weeks. The company's valuation could see additional upside should the oral formulation data prove positive.

The reiterated Buy rating and new price target reflect the analyst's optimism about the drug's market potential and Viking Therapeutics' growth prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.